Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials

被引：46

作者：

Langbaum, Jessica B. ^{[1
]}

Zissimopoulos, Julie ^{[2
,3
]}

Au, Rhoda ^{[4
,5
,6
,7
,8
,9
]}

Bose, Niranjan ^{[10
]}

Edgar, Chris J. ^{[11
]}

Ehrenberg, Evan ^{[12
]}

Fillit, Howard ^{[13
]}

Hill, Carl, V ^{[14
]}

Hughes, Lynne ^{[15
]}

Irizarry, Michael ^{[16
]}

Kremen, Sarah ^{[17
]}

Lakdawalla, Darius ^{[3
]}

Lynn, Nancy ^{[18
]}

Malzbender, Kristina ^{[10
]}

Maruyama, Tetsuyuki ^{[19
]}

Massett, Holly A. ^{[20
]}

Patel, Deep ^{[21
]}

Peneva, Desi ^{[3
]}

Reiman, Eric M. ^{[1
]}

Romero, Klaus ^{[22
]}

Routledge, Carol ^{[23
]}

Weiner, Michael W. ^{[24
,25
,26
,27
]}

Weninger, Stacie ^{[28
]}

Aisen, Paul S. ^{[29
]}

机构：

[1] Banner Alzheimers Inst, Phoenix, AZ USA

[2] Univ Southern Calif, Sol Price Sch Publ Policy, 635 Downey Way, Los Angeles, CA 90089 USA

[3] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, 635 Downey Way, Los Angeles, CA 90089 USA

[4] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA

[5] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA

[6] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA USA

[7] Boston Univ, Sch Publ Hlth, Dept Anat & Neurobiol, Boston, MA USA

[8] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA USA

[9] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[10] Gates Ventures, Kirkland, WA USA

[11] Cogstate Ltd, Reading, Berks, England

[12] Clara Hlth, San Francisco, CA USA

[13] Alzheimers Drug Discovery Fdn, New York, NY USA

[14] Alzheimers Assoc, Chicago, IL USA

[15] Lynne Hughes Consulting, Bracknell, Berks, England

[16] Eisai, Woodcliff Lake, NJ USA

[17] Cedars Sinai Med Ctr, Dept Neurol, Jona Goldrich Ctr Alzheimers & Memory Disorders, Los Angeles, CA 90048 USA

[18] BrightFocus Fdn, Clarksburg, MD USA

[19] Alzheimers Dis Data Initiat, Kirkland, WA USA

[20] NIH, Bldg 10, Bethesda, MD 20892 USA

[21] IQVIA, New York, NY USA

[22] Crit Path Inst, Tucson, AZ USA

[23] Small Pharma Ltd, London, England

[24] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA

[25] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[26] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA

[27] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[28] FBRI, Cambridge, MA USA

[29] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA

来源：

ALZHEIMERS & DEMENTIA | 2023年 / 19卷 / 02期

关键词：

Alzheimer's disease; clinical trials; diversity in clinical trials; recruitment; retention; trial participation; BLOOD-BASED BIOMARKERS; ANNUAL WELLNESS VISIT; DEMENTIA CARE; POPULATIONS; CAREGIVERS; RETENTION; PARTNERS;

D O I：

10.1002/alz.12737

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient-advocacy organizations, philanthropy, non-profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimer's clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panel's recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD.

引用

页码：696 / 707

页数：12

共 50 条

[21] Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations
Bukhari, Syed Nasir Abbas
CURRENT DRUG DELIVERY, 2022, 19 (01) : 17 - 31
[22] Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials
Kristin Kahle-Wrobleski
Howard Fillit
Jonathan Kurlander
Catherine Reed
Mark Belger
The European Journal of Health Economics, 2015, 16 : 995 - 1004
[23] Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials
Kahle-Wrobleski, Kristin
Fillit, Howard
Kurlander, Jonathan
Reed, Catherine
Belger, Mark
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (09): : 995 - 1004
[24] Clinical Trials and Alzheimer's Disease: A Webliography
Howard, Allison
JOURNAL OF CONSUMER HEALTH ON THE INTERNET, 2014, 18 (01) : 67 - 80
[25] Clinical Methodology of Alzheimer’s Disease Trials
Julian A. Gray
Drug information journal : DIJ / Drug Information Association, 1999, 33 (1): : 245 - 252
[26] CONFUSION IN CLINICAL TRIALS OF ALZHEIMER'S DISEASE
Hobart, Jeremy
Cleanthous, Sophie
Zajieck, John
Cano, Stefan
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
[27] Globalization of Alzheimer's disease clinical trials
Cummings, Jeffrey
Reynders, Robert
Zhong, Kate
ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (04)
[28] Clinical methodology of Alzheimer's disease trials
Gray, JA
DRUG INFORMATION JOURNAL, 1999, 33 (01): : 245 - 252
[29] Globalization of Alzheimer's disease clinical trials
Jeffrey Cummings
Robert Reynders
Kate Zhong
Alzheimer's Research & Therapy, 3
[30] Alzheimer's disease failed clinical trials
Asher, Shreya
Priefer, Ronny
LIFE SCIENCES, 2022, 306

← 1 2 3 4 5 →